Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Exp Pathol ; 97(5): 389-396, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27918111

RESUMEN

Severe chronic hepatic injury can induce complex reparative processes. Ductular reaction and the appearance of small hepatocytes are standard components of this response, which is thought to have both adverse (e.g. fibrosis, carcinogenesis) and beneficial (regeneration) consequences. This complex tissue reaction is regulated by orchestrated cytokine action. We have investigated the influence of the tyrosine kinase inhibitor imatinib on a regenerative process. Ductular reaction was induced in mice by the widely used choline-deficient ethionine-supplemented diet (CDE). Test animals were treated daily with imatinib. After 6 weeks of treatment, imatinib successfully reduced the extent of ductular reaction and fibrosis in the CDE model. Furthermore, the number of small hepatocytes increased, and these cells had high proliferative activity, were positive for hepatocyte nuclear factor 4 and expressed high levels of albumin and peroxisome proliferator-activated receptor alpha. The overall functional zonality of the hepatic parenchyma (cytochrome P450 2E1 and glucose 6 phosphatase activity; endogenous biotin content) was maintained. The expression of platelet-derived growth factor receptor beta, which is the major target of imatinib, was downregulated. The anti-fibrotic activity of imatinib has already been reported in several experimental models. Additionally, in the CDE model imatinib was able to enhance regeneration and preserve the functional arrangement of hepatic lobules. These results suggest that imatinib might promote the recovery of the liver following parenchymal injury through the inhibition of platelet-derived growth factor receptor beta.


Asunto(s)
Mesilato de Imatinib/farmacología , Cirrosis Hepática/tratamiento farmacológico , Regeneración Hepática/efectos de los fármacos , Inhibidores de Proteínas Quinasas/farmacología , Células Madre/efectos de los fármacos , Animales , Deficiencia de Colina/complicaciones , Suplementos Dietéticos , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Etionina , Hepatocitos/efectos de los fármacos , Hepatocitos/patología , Mesilato de Imatinib/uso terapéutico , Cirrosis Hepática/etiología , Cirrosis Hepática/patología , Cirrosis Hepática/fisiopatología , Masculino , Ratones Endogámicos C57BL , Inhibidores de Proteínas Quinasas/uso terapéutico , Células Madre/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA